Critical Comparison: Metagenomi (MGX) & Its Rivals

Metagenomi (NASDAQ:MGX) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Metagenomi to similar companies based on the strength of its dividends, institutional ownership, analyst recommendations, profitability, earnings, valuation and risk.

Profitability

This table compares Metagenomi and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-134.27%	-43.23%	-18.86%
Metagenomi Competitors	-2,185.76%	-161.46%	-40.62%

Valuation & Earnings

This table compares Metagenomi and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metagenomi	$52.30 million	-$68.25 million	-0.57
Metagenomi Competitors	$575.26 million	-$70.96 million	-2.05

Metagenomi’s competitors have higher revenue, but lower earnings than Metagenomi. Metagenomi is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Metagenomi has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Comparatively, Metagenomi’s competitors have a beta of -4.48, suggesting that their average share price is 548% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Metagenomi and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	0	0	4	0	3.00
Metagenomi Competitors	1973	5466	14073	305	2.58

Metagenomi currently has a consensus price target of $14.75, indicating a potential upside of 889.93%. As a group, “Biological products, except diagnostic” companies have a potential upside of 117.59%. Given Metagenomi’s stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than its competitors.

Summary

Metagenomi beats its competitors on 9 of the 13 factors compared.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.